Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

TPEX:7427 Statistics

Total Valuation

TPEX:7427 has a market cap or net worth of TWD 1.74 billion. The enterprise value is 1.25 billion.

Market Cap	1.74B
Enterprise Value	1.25B

Important Dates

The next estimated earnings date is Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

TPEX:7427 has 42.95 million shares outstanding. The number of shares has increased by 12.53% in one year.

Current Share Class	42.95M
Shares Outstanding	42.95M
Shares Change (YoY)	+12.53%
Shares Change (QoQ)	-0.87%
Owned by Insiders (%)	13.09%
Owned by Institutions (%)	n/a
Float	35.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	976.72
PB Ratio	3.09
P/TBV Ratio	3.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-14.22
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-15.67

Financial Position

The company has a current ratio of 30.32, with a Debt / Equity ratio of 0.02.

Current Ratio	30.32
Quick Ratio	28.91
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.11
Interest Coverage	-809.38

Financial Efficiency

Return on equity (ROE) is -14.21% and return on invested capital (ROIC) is -9.11%.

Return on Equity (ROE)	-14.21%
Return on Assets (ROA)	-8.88%
Return on Invested Capital (ROIC)	-9.11%
Return on Capital Employed (ROCE)	-16.05%
Revenue Per Employee	118,733
Profits Per Employee	-5.85M
Employee Count	18
Asset Turnover	0.00
Inventory Turnover	0.24

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +25.08% in the last 52 weeks. The beta is -0.12, so TPEX:7427's price volatility has been lower than the market average.

Beta (5Y)	-0.12
52-Week Price Change	+25.08%
50-Day Moving Average	36.32
200-Day Moving Average	35.16
Relative Strength Index (RSI)	54.24
Average Volume (20 Days)	1,105,876

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TPEX:7427 had revenue of TWD 1.78 million and -87.75 million in losses. Loss per share was -2.03.

Revenue	1.78M
Gross Profit	1.07M
Operating Income	-91.46M
Pretax Income	-87.75M
Net Income	-87.75M
EBITDA	-86.67M
EBIT	-91.46M
Loss Per Share	-2.03

Balance Sheet

The company has 500.57 million in cash and 8.91 million in debt, with a net cash position of 491.66 million or 11.45 per share.

Cash & Cash Equivalents	500.57M
Total Debt	8.91M
Net Cash	491.66M
Net Cash Per Share	11.45
Equity (Book Value)	563.86M
Book Value Per Share	13.13
Working Capital	508.21M

Cash Flow

In the last 12 months, operating cash flow was -79.56 million and capital expenditures -99,000, giving a free cash flow of -79.66 million.

Operating Cash Flow	-79.56M
Capital Expenditures	-99,000
Free Cash Flow	-79.66M
FCF Per Share	-1.85

Margins

Gross Margin	59.80%
Operating Margin	-5,135.32%
Pretax Margin	-4,927.12%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TPEX:7427 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.53%
Shareholder Yield	-12.53%
Earnings Yield	-5.04%
FCF Yield	-4.58%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TPEX:7427 has an Altman Z-Score of 41.47 and a Piotroski F-Score of 2.

Altman Z-Score	41.47
Piotroski F-Score	2